Specification :

By name Tetramethyl-5-( 1H-1, 2, 4-triazol-1ylmethyl) 1, 3-benzenediacetionitrile

CAS NO. 120511-72-0
Molecular formula C15H18N2 226.32

Specification 99 percent
Melting point 81-82 C
Appearance white or white crystalline powder

Anastrozole is a new, highly selective nonsteroidal aromatase inhibitor indicated for the endocrine treatment of postmenopausal women with advanced breast cancer. In postmenopausal women, anastrozole prevent the synthesis of estrogens and significantly reduced plasma estrogen levels, and this has been associated with tumour regression in patients with estrogen-dependent breast cancer. Absorption of anastrozole was rapid and virtually complete after oral administration. The 1 mg per day of anastrozole is highly selective and well tolerated by patients. It has a terminal half life ( 30-50 h) long enough to provide for once- daily dosing and this dose produces the maximum detectable estradiol suppression. In this paper, we reviewed its mechanism, pharmacokinetics and clinical use.